Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19718025 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Lapatinib in Stage IV Melanoma With ERBB4 Mutations
Condition: Malignant Melanoma
Intervention: Drug: Lapatinib

Indicates status has not been verified in more than two years